A high-level overview of GCL Global Holdings Ltd (GCL) stock. View (GCL) real-time stock price, chart, news, analysis, analyst reviews and more.

Glaucoma is an irreversible neurodegenerative disease, where intraocular hypertension is developed due to the increased aqueous humor and blockage of the drainage system between the iris and cornea.

Glaucoma is a neurodegenerative disease that affects the optic nerve head and causes visual field defect. Current investigations focus on neural component which may overlook other important factors ...

Send comments and news tips to news@medscape.net. Cite this: Edited by Shrabasti Bhattacharya. Intensive Bevacizumab Boosts Vision in Macular Degeneration - Medscape - June 19, 2025.

Asif M, Asif A, Rahman UA, et al. Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: a systematic review and meta-analysis. 2025;8:e70059. doi:10.1002/edm2 ...

Founder Group has entered a memorandum of understanding (MoU) with GCL Systems Integration Technology to develop renewable energy projects across Malaysia and other ASEAN countries, with potential ...

DOI: 10.1093/pnasnexus/pgaf168 Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by high pressure inside the eye.

HealthDay News — Diagnosis of primary open-angle glaucoma (POAG) is associated with a reduction in mental health scores, according to a study published online June 5 in JAMA Ophthalmology. Mae O ...

Patients with challenging diabetic macular edema (DME) whose central subfield thickness (CST) stays too high, or does not improve despite single-pathway biologic therapy can achieve anatomical gains ...

Aim To analyse a new grading protocol for clinically significant diabetic macular oedema (CSME) based on spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA). Methods ...

Source Reference: Shor R, et al "Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration" JAMA Ophthalmol 2025; DOI: 10.1001/jamaophthalmol.2025.1455.

The company’s lead program, QLS-111, is designed to address a significant unmet need in glaucoma treatment by targeting EVP. For more information, please visit www.qlaris.bio.